Vaccines Firm Goes to Vivalis in All-Share Deal Worth $175M
By Nuala Moran
Tuesday, December 18, 2012
LONDON The French vaccines manufacturing technology company Vivalis SA is acquiring Austrian vaccines discoverer and developer Intercell AG, of Vienna, in an all-share deal valued at €133 million (US$175 million).
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.